Jan C. Drooger

584 total citations
19 papers, 243 citations indexed

About

Jan C. Drooger is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Jan C. Drooger has authored 19 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Genetics and 6 papers in Cancer Research. Recurrent topics in Jan C. Drooger's work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers) and Breast Cancer Treatment Studies (5 papers). Jan C. Drooger is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers) and Breast Cancer Treatment Studies (5 papers). Jan C. Drooger collaborates with scholars based in Netherlands and India. Jan C. Drooger's co-authors include Agnes Jager, Stefan Sleijfer, Caroline Seynaeve, Maartje J. Hooning, Inge Marie Obdeijn, A. J. G. Swaak, Margreet H.A. Baaijens, A Dees, Mark‐David Levin and Hánah N. Rier and has published in prestigious journals such as Cancer, International Journal of Cancer and European Journal of Pharmacology.

In The Last Decade

Jan C. Drooger

18 papers receiving 238 citations

Peers

Countries citing papers authored by Jan C. Drooger

Since Specialization

Citations

This map shows the geographic impact of Jan C. Drooger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan C. Drooger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan C. Drooger more than expected).

Fields of papers citing papers by Jan C. Drooger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan C. Drooger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan C. Drooger. The network helps show where Jan C. Drooger may publish in the future.

Co-authorship network of co-authors of Jan C. Drooger

This figure shows the co-authorship network connecting the top 25 collaborators of Jan C. Drooger. A scholar is included among the top collaborators of Jan C. Drooger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan C. Drooger. Jan C. Drooger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy 2025 ·The Breast ·(unknown), (unknown), (unknown), Jan C. Drooger, (unknown), (unknown), Yvonne V. Louwers, Jenny A. Visser, Joop S.E. Laven, Agnes Jager	0
2	Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial 2024 ·Breast Cancer Research and Treatment ·(unknown), (unknown), (unknown), Mai N. Van, Jaco Kraan, Jan C. Drooger, Johanna M. Zuetenhorst, Saskia M. Wilting, Stefan Sleijfer, Agnes Jager, John W.M. Martens	3
3	The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer 2023 ·ESMO Open ·(unknown), Esther Oomen‐de Hoop, C. Louwrens Braal, (unknown), Jan C. Drooger, (unknown), (unknown), Stijn L.W. Koolen, Agnes Jager, Ron H.J. Mathijssen	10
4	Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival 2023 ·npj Breast Cancer ·(unknown), Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, (unknown), Agnes Jager, Stefan Sleijfer, John W.M. Martens, Saskia M. Wilting	6
5	The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study 2023 ·Cancer ·(unknown), Maartje J. Hooning, Carolien H. M. van Deurzen, (unknown), Jan C. Drooger, Jos Kitzen, John W.M. Martens, (unknown), (unknown), (unknown), Bernadette A. M. Heemskerk‐Gerritsen, Agnes Jager	2
6	The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction 2022 ·International Journal of Cancer ·(unknown), Tessa G. Steenbruggen, Hánah N. Rier, Jos Kitzen, Carolien H. Smorenburg, (unknown), Paul C. de Jong, Jan C. Drooger, Cynthia Holterhues, Marcel J.M. Kofflard, Eric Boersma, Gabe S. Sonke, Mark‐David Levin, Agnes Jager	5
7	Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer 2022 ·JAMA Network Open ·(unknown), (unknown), Jan C. Drooger, Joan B. Heijns, (unknown), (unknown), Daan Nieboer, Joachim G.J.V. Aerts, Agnes van der Heide, Carin C.D. van der Rijt	10
8	Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring? 2021 ·Breast Cancer Research and Treatment ·(unknown), Tessa G. Steenbruggen, Joost van Rosmalen, Hánah N. Rier, Jos Kitzen, (unknown), Albert J. ten Tije, P.C. de Jong, Jan C. Drooger, Cynthia Holterhues, Carolien H. Smorenburg, Marcel J.M. Kofflard, Eric Boersma, Gabe S. Sonke, Mark‐David Levin, Agnes Jager	20
9	Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab? 2019 ·Breast Cancer Research and Treatment ·Tessa G. Steenbruggen, (unknown), Carolien H. Smorenburg, Hánah N. Rier, Agnes Jager, Karin Beelen, Albert J. ten Tije, P.C. de Jong, Jan C. Drooger, Cynthia Holterhues, Jos Kitzen, Mark‐David Levin, Gabe S. Sonke	15
10	First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy 2017 ·The Oncologist ·Hánah N. Rier, Mark‐David Levin, Joost van Rosmalen, Monique M.E.M. Bos, Jan C. Drooger, Paul de Jong, Johanneke E.A. Portielje, (unknown), (unknown), Stefan Sleijfer, Agnes Jager	16
11	Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies 2017 ·International Journal of Hyperthermia ·Nathalie van den Tempel, Hanny Odijk, (unknown), Kishan A.T. Naipal, Anja Raams, Berina Eppink, Dik C. van Gent, José A. Hardillo, Gerda M. Verduijn, Jan C. Drooger, Gerard C. van Rhoon, (unknown), Helena C. van Doorn, Joost L. Boormans, Agnes Jager, Martine Franckena, Roland Kanaar	20
12	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial 2016 ·Cancer ·Jan C. Drooger, Harm van Tinteren, (unknown), Albert J. ten Tije, Hiltje de Graaf, Johanneke E.A. Portielje, Agnes Jager, Aafke H. Honkoop, Sabine C. Linn, Judith R. Kroep, Frans Erdkamp, Paul Hamberg, Alex L.T. Imholz, (unknown), Joan B. Heijns, A. Elise van Leeuwen‐Stok, Stefan Sleijfer	3
13	Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer 2016 ·Breast Cancer Research and Treatment ·Jan C. Drooger, B.A.M. Heemskerk-Gerritsen, (unknown), (unknown), Caroline Seynaeve, Agnes Jager	17
14	Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study 2015 ·Medical Oncology ·Jan C. Drooger, (unknown), (unknown), Agnes Jager, Felix E. de Jongh	5
15	Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair 2015 ·Journal of Pharmaceutical and Biomedical Analysis ·Jan C. Drooger, Agnes Jager, (unknown), (unknown), Stefan Sleijfer, Ron H.J. Mathijssen, Peter de Bruijn	15
16	Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age 2015 ·Breast Cancer Research and Treatment ·Jan C. Drooger, (unknown), Jean‐Philippe Pignol, Linetta B. Koppert, (unknown), Caroline Seynaeve, Maartje J. Hooning, Agnes Jager	22
17	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature 2014 ·Cancer Treatment Reviews ·Jan C. Drooger, Maartje J. Hooning, Caroline Seynaeve, Margreet H.A. Baaijens, Inge Marie Obdeijn, Stefan Sleijfer, Agnes Jager	38
18	Denosumab in breast cancer treatment 2013 ·European Journal of Pharmacology ·Jan C. Drooger, (unknown), Stefan Sleijfer, Agnes Jager	20
19	ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics 2009 ·The Open Rheumatology Journal ·Jan C. Drooger, A Dees, A. J. G. Swaak	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact